Biohaven Pharmaceutical Holding Company Ltd.

NYSE:BHVN

39.31 (USD) • At close February 4, 2025
Bedrijfsnaam Biohaven Pharmaceutical Holding Company Ltd.
Symbool BHVN
Munteenheid USD
Prijs 39.31
Beurswaarde 3,975,115,490
Dividendpercentage 0%
52-weken bereik 26.8 - 62.21
Industrie Biotechnology
Sector Healthcare
CEO Dr. Vladimir Coric M.D.
Website https://www.biohavenpharma.com

An error occurred while fetching data.

Over Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III

Vergelijkbare Aandelen

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)